FI3661510T3 - Menetelmiä käyttäytymismuutosten hoitamiseksi - Google Patents
Menetelmiä käyttäytymismuutosten hoitamiseksi Download PDFInfo
- Publication number
- FI3661510T3 FI3661510T3 FIEP18748921.6T FI18748921T FI3661510T3 FI 3661510 T3 FI3661510 T3 FI 3661510T3 FI 18748921 T FI18748921 T FI 18748921T FI 3661510 T3 FI3661510 T3 FI 3661510T3
- Authority
- FI
- Finland
- Prior art keywords
- use according
- pharmaceutical composition
- compound
- behavioral change
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382544 | 2017-08-03 | ||
| EP17382545 | 2017-08-03 | ||
| EP18382299 | 2018-04-30 | ||
| PCT/EP2018/071120 WO2019025588A1 (en) | 2017-08-03 | 2018-08-03 | METHODS OF TREATING ALTERATIONS IN BEHAVIOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3661510T3 true FI3661510T3 (fi) | 2024-12-18 |
Family
ID=63077881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18748921.6T FI3661510T3 (fi) | 2017-08-03 | 2018-08-03 | Menetelmiä käyttäytymismuutosten hoitamiseksi |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20200323828A1 (enExample) |
| EP (2) | EP4512473A3 (enExample) |
| JP (2) | JP2020529995A (enExample) |
| KR (3) | KR102685898B1 (enExample) |
| CN (1) | CN110996949A (enExample) |
| AU (2) | AU2018309372B2 (enExample) |
| BR (1) | BR112020000827A2 (enExample) |
| DK (1) | DK3661510T3 (enExample) |
| ES (1) | ES3001085T3 (enExample) |
| FI (1) | FI3661510T3 (enExample) |
| HR (1) | HRP20241716T1 (enExample) |
| HU (1) | HUE069697T2 (enExample) |
| IL (1) | IL272092B2 (enExample) |
| LT (1) | LT3661510T (enExample) |
| MX (2) | MX2020001323A (enExample) |
| MY (1) | MY204406A (enExample) |
| PH (1) | PH12020500211A1 (enExample) |
| PL (1) | PL3661510T3 (enExample) |
| RS (1) | RS66336B1 (enExample) |
| SG (1) | SG11202000077RA (enExample) |
| SI (1) | SI3661510T1 (enExample) |
| WO (1) | WO2019025588A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013698B2 (en) | 2016-03-15 | 2021-05-25 | Oryzon Genomics S.A. | Combinations of LSD1 inhibitors for the treatment of hematological malignancies |
| SI3661510T1 (sl) * | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
| US20220151999A1 (en) * | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| US20220151998A1 (en) * | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN114615979A (zh) * | 2019-09-03 | 2022-06-10 | 奥莱松基因组股份有限公司 | 用于治疗孤独症谱系障碍的伐菲德司他 |
| WO2021058024A1 (zh) * | 2019-09-29 | 2021-04-01 | 南京明德新药研发有限公司 | Lsd1抑制剂 |
| CN118604352B (zh) * | 2024-05-22 | 2025-08-01 | 暨南大学 | Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR20080088570A (ko) | 2005-08-10 | 2008-10-02 | 더 존스 홉킨스 유니버시티 | 항기생충 및 항암 치료제 및 라이신-특이적인 디메틸라제억제제로 유용한 폴리아민 |
| EP2142287A4 (en) | 2007-04-13 | 2012-05-23 | Univ Johns Hopkins | INHIBITORS OF LYSINPECIFIC DEMETHYLASE |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| WO2010143582A1 (ja) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| MX2012012111A (es) | 2010-04-19 | 2013-05-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especifica de lisina y su uso. |
| AU2011244478B2 (en) | 2010-04-20 | 2014-07-17 | Fondazione IEO-CCM | Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2 |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| SI2598482T1 (sl) * | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| CA2831143C (en) | 2011-03-25 | 2019-05-21 | Glaxosmithkline Intellectual Property Development Limited | Cyclopropylamines as lsd1 inhibitors |
| UA114406C2 (uk) | 2011-08-09 | 2017-06-12 | Такеда Фармасьютікал Компані Лімітед | Похідні циклопропанаміну як інгібітори lsd1 |
| SG2014009609A (en) * | 2011-08-15 | 2014-05-29 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| CN107266345B (zh) | 2011-10-20 | 2021-08-17 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
| US9751885B2 (en) | 2012-10-12 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| EP2927212A4 (en) | 2012-11-28 | 2016-06-08 | Univ Kyoto | LSD1-SELECTIVE HEMMER WITH LYSINE STRUCTURE |
| US9144555B2 (en) | 2012-11-30 | 2015-09-29 | Darlene E. McCord | Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| KR102288648B1 (ko) | 2013-06-19 | 2021-08-12 | 유니버시티 오브 유타 리서치 파운데이션 | 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체 |
| CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用 |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| PL3080100T3 (pl) | 2013-12-11 | 2023-03-06 | Celgene Quanticel Research, Inc. | Inhibitory lizyno-specyficznej demetylazy-1 |
| US10118903B2 (en) | 2014-02-07 | 2018-11-06 | Musc Foundation For Research Development | Aminotriazole-based KDM1A inhibitors as epigenetic modulators |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| SG11201608340UA (en) | 2014-04-11 | 2016-11-29 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| HUE057895T2 (hu) | 2014-05-01 | 2022-06-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| AU2015265820C1 (en) | 2014-05-30 | 2020-01-16 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| MX376632B (es) | 2014-06-27 | 2025-03-07 | Celgene Quanticel Res Inc | Inhibidores de demetilasa-1 especifica de lisina. |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| EA033698B1 (ru) | 2014-07-03 | 2019-11-18 | Celgene Quanticel Res Inc | Ингибиторы лизинспецифической деметилазы-1 |
| MX391865B (es) | 2014-07-03 | 2025-03-21 | Celgene Quanticel Res Inc | Inhibidores de demetilasa-1 especifica de lisina. |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| ES2935114T3 (es) | 2014-09-05 | 2023-03-01 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| WO2016123387A1 (en) | 2015-01-30 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| KR102626978B1 (ko) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | 질환 치료를 위한 kdm1a 저해제 |
| CN106146361A (zh) | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| CN106045862B (zh) | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| US20170001970A1 (en) | 2015-07-02 | 2017-01-05 | University Of Utah Research Foundation | Substituted benzohydrazide analogs as histone demethylase inhibitors |
| JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Ｌｓｄ１阻害剤の塩 |
| RS61404B1 (sr) | 2015-11-05 | 2021-02-26 | Celgene Quanticel Research Inc | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primena u lečenju kancera |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| CA3006434C (en) | 2015-11-27 | 2021-03-16 | Taiho Pharmaceutical Co., Ltd. | Biphenyl compound or salt thereof |
| WO2017109061A1 (en) | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| SG11201805645QA (en) | 2015-12-29 | 2018-07-30 | Mirati Therapeutics Inc | Lsd1 inhibitors |
| BR112018013074A2 (en) | 2015-12-30 | 2018-12-11 | Novartis Ag | immune effector cell therapies with enhanced efficacy |
| CN110267945A (zh) | 2016-03-01 | 2019-09-20 | 诺华股份有限公司 | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 |
| CN107200706A (zh) | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| US20170283397A1 (en) | 2016-03-31 | 2017-10-05 | University Of Utah Research Foundation | Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors |
| SI3455204T1 (sl) | 2016-05-09 | 2026-03-31 | Jubilant Epicore LLC | Ciklopropil-amidne spojine kot dvojni zaviralci lsd1/hdac |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| CN107513068A (zh) | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| CN106478639B (zh) | 2016-09-05 | 2018-09-18 | 郑州大学 | 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用 |
| CN106432248B (zh) | 2016-09-27 | 2018-11-27 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| WO2018081342A1 (en) | 2016-10-26 | 2018-05-03 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| MD3532459T2 (ro) | 2016-10-26 | 2024-06-30 | Constellation Pharmaceuticals Inc | Inhibitori ai LSD1 și utilizările medicale ale acestora |
| CN106831489B (zh) | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| CN106928235A (zh) | 2017-05-03 | 2017-07-07 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| SI3661510T1 (sl) * | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
-
2018
- 2018-08-03 SI SI201831191T patent/SI3661510T1/sl unknown
- 2018-08-03 HR HRP20241716TT patent/HRP20241716T1/hr unknown
- 2018-08-03 KR KR1020207006287A patent/KR102685898B1/ko active Active
- 2018-08-03 KR KR1020267000840A patent/KR20260015998A/ko active Pending
- 2018-08-03 PL PL18748921.6T patent/PL3661510T3/pl unknown
- 2018-08-03 LT LTEPPCT/EP2018/071120T patent/LT3661510T/lt unknown
- 2018-08-03 AU AU2018309372A patent/AU2018309372B2/en active Active
- 2018-08-03 MX MX2020001323A patent/MX2020001323A/es unknown
- 2018-08-03 MY MYPI2020000100A patent/MY204406A/en unknown
- 2018-08-03 BR BR112020000827-3A patent/BR112020000827A2/pt unknown
- 2018-08-03 JP JP2020505367A patent/JP2020529995A/ja active Pending
- 2018-08-03 US US16/635,704 patent/US20200323828A1/en not_active Abandoned
- 2018-08-03 IL IL272092A patent/IL272092B2/en unknown
- 2018-08-03 FI FIEP18748921.6T patent/FI3661510T3/fi active
- 2018-08-03 HU HUE18748921A patent/HUE069697T2/hu unknown
- 2018-08-03 ES ES18748921T patent/ES3001085T3/es active Active
- 2018-08-03 DK DK18748921.6T patent/DK3661510T3/da active
- 2018-08-03 RS RS20241411A patent/RS66336B1/sr unknown
- 2018-08-03 CN CN201880050319.1A patent/CN110996949A/zh active Pending
- 2018-08-03 KR KR1020247023305A patent/KR102912513B1/ko active Active
- 2018-08-03 SG SG11202000077RA patent/SG11202000077RA/en unknown
- 2018-08-03 EP EP24205125.8A patent/EP4512473A3/en active Pending
- 2018-08-03 EP EP18748921.6A patent/EP3661510B1/en active Active
- 2018-08-03 WO PCT/EP2018/071120 patent/WO2019025588A1/en not_active Ceased
-
2020
- 2020-01-28 PH PH12020500211A patent/PH12020500211A1/en unknown
- 2020-01-31 MX MX2023009388A patent/MX2023009388A/es unknown
-
2023
- 2023-08-18 US US18/451,897 patent/US20240277673A1/en active Pending
- 2023-08-24 JP JP2023136283A patent/JP7829235B2/ja active Active
-
2024
- 2024-11-14 AU AU2024264660A patent/AU2024264660A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| MX2022013410A (es) | Metodos de tratamiento. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2021002321A (es) | Nuevos metodos. | |
| TN2017000119A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| JP2020529995A5 (enExample) | ||
| EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| WO2016109217A3 (en) | Btk inhibitors | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| MX389330B (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MY199237A (en) | Methods of treating ocular conditions | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| WO2017029588A3 (en) | Mdm2 inhibitors for treating uveal melanoma |